Article

Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

Cutis. 2014 March;93(3):131
By
Anthony M. Rossi, MD
Author and Disclosure Information

Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is edited by Michael J. Murphy, MD, and reviewed by Anthony M. Rossi, MD. The future of highly targeted therapies for cancer is here, and for any clinician treating malignant melanoma, a solid understanding of these therapies is needed.
PDF Download

 

Recommended Reading

IBD linked to increased risk of certain cancers
MDedge Dermatology
Skin cancer risk stands out in anti-TNF biologics use
MDedge Dermatology
Product News: 02 2014
MDedge Dermatology
Cosmetic Corner: Dermatologists Weigh in on Sunless Tanners
MDedge Dermatology
Final results validate sentinel-node biopsy for melanoma
MDedge Dermatology
Ingenol mebutate improves outcomes in actinic keratosis
MDedge Dermatology
Youth tanning curbed in states with restrictions
MDedge Dermatology
Video intervention inspires men to undergo skin exams
MDedge Dermatology
Aggressive secondary squamous carcinoma appeared during BRAF inhibitor targeted therapy
MDedge Dermatology
Counterphobia and Poor Sun Protection Practices in First-Degree Relatives of Melanoma Patients
MDedge Dermatology